PT - JOURNAL ARTICLE AU - Francesco Pinotti AU - Paul S Wikramaratna AU - Uri Obolski AU - Robert S Paton AU - Daniel S C Damineli AU - Luiz C J Alcantara AU - Marta Giovanetti AU - Sunetra Gupta AU - José Lourenço TI - Potential impact of individual exposure histories to endemic human coronaviruses on age-dependence in severity of COVID-19 AID - 10.1101/2020.07.23.20154369 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.23.20154369 4099 - http://medrxiv.org/content/early/2020/07/26/2020.07.23.20154369.short 4100 - http://medrxiv.org/content/early/2020/07/26/2020.07.23.20154369.full AB - Cross-reactivity to SARS-CoV-2 from previous exposure to endemic coronaviruses (eHCoV) is gaining increasing attention as a possible driver of both protection against infection and severity of COVID-19 disease. Here, we use a stochastic individual-based model to show that heterogeneities in individual exposure histories to endemic coronaviruses are able to explain observed age patterns of hospitalisation due to COVID-19 in EU/EEA countries and the UK, provided there is (i) a decrease in cross-protection to SARS-CoV-2 with the number of eHCoV exposures and (ii) an increase in potential disease severity with number of eHCoV exposures or as a result of immune senescence. We also show that variation in health care capacity and testing efforts is compatible with country-specific differences in hospitalisation rates. Our findings call for further research on the role of cross-reactivity to endemic coronaviruses and highlight potential challenges arising from heterogeneous health care capacity and testing.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFP was funded by the UKRI GCRF One Health Poultry Hub (Grant No. BB/S011269/1), one of twelve interdisciplinary research hubs funded under the UK government’s Grand Challenge Research Fund Interdisciplinary Research Hub initiative. JL was supported by a Lectureship from the Department of Zoology, University of Oxford. SG acknowledges funding from the ERC UNIFLUVAC (812816) and MRC CiC 6 as well the Georg und Emily Von Opel Foundation. DSCD is funded by the grant 19/23343-7 and 2020/06160-3 from the Säo Paulo Research Foundation (FAPESP). MG is supported by Fundaçäo de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ). LCJA acknowledges funding from PAHO (Pan American Health Organization) SCON2019-00572 (SCON2018-00572). UO and PW declare no funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRBAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData from The European Surveillance System - TESSy, provided by Austria, Croatia, Cyprus, Estonia, Finland, Germany, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Slovakia, United Kingdom and released by ECDC. https://covid19-surveillance-report.ecdc.europa.eu/